Results 21 to 30 of about 682 (125)

Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19).
Jing Zhang, Fang Wang, Ying Xie, Qianyu Li, Zhenzhen Zhu, Yuan Dong   +5 more
doaj   +2 more sources

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]

BMJ Open
Objectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang, Zhigang Ren, Xiaoli Jin, Hong Luo, Donghua Zhang, Ming Cheng, Fuwei Wang, Bohan Jia, Guotao Li, Mengzhao Yang, Guangming Li, Shixi Zhang, Guowu Qian, Silin Li, Hongxia Liang   +14 more
doaj   +2 more sources

Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study

Frontiers in Immunology, 2023
BackgroundCurrent guidelines prioritize the use of Azvudine in Coronavirus Disease 2019 (COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients are still lacking.
Guangtong Deng, Yating Dian, Zeng Furong   +2 more
exaly   +3 more sources

Evaluation of the efficacy and mechanisms of azvudine in elderly patients with malignant tumors complicated by COVID-19 [PDF]

Acta Pharmaceutica Sinica B
Sun R, Song Y, Li Z, Wang D, Yu Z.
exaly   +5 more sources

Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort study [PDF]

Scientific Reports
Hypertension is widely acknowledged as a major risk factor for disease severity and death in patients with coronavirus disease 2019 (COVID-19). Azvudine is recommended for COVID-19 patients in China.
Yu Chen, Huan Li, Yichen Ma, Ling Wang, Guowu Qian, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yun Zheng, Qin Bai, Haiyu Wang, Zhigang Ren   +14 more
doaj   +2 more sources

Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study [PDF]

Signal Transduction and Targeted Therapy
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized
Haiyu Wang, Guangying Cui, Ming Cheng, Tuerganaili Aji, Guotao Li, Xinjun Hu, Guangming Li, Shixi Zhang, Yanyang Zhang, Linqi Diao, Pan Li, Ling Wang, Yiqiang Yuan, Guowu Qian, Ruiqing Zhang, Xiaoli Jin, Juan Wang, Hong Luo, Donghua Zhang, Mingming Wang, Silin Li, Zhan Song, Mengzhao Yang, Guanyue Su, Ranran Sun, Junbiao Chang, Zujiang Yu, Zhigang Ren   +27 more
doaj   +2 more sources

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases [PDF]

Virology Journal
Background Azvudine and nirmatrelvir/ritonavir are recommended as priority treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in patients with pre-existing chronic liver diseases remains unknown.
Guanyue Su, Feng Gao, Mengzhao Yang, Ling Wang, Lili Liang, Silin Li, Guangming Li, Na Han, Guotao Li, Guowu Qian, Shixi Zhang, Hong Luo, Donghua Zhang, Hongxia Liang, Zhigang Ren   +14 more
doaj   +2 more sources

Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study [PDF]

Acta Pharmaceutica Sinica B
Debates persist regarding the efficacy and safety of azvudine, particularly its real-world outcomes. This study involved patients aged ≥60 years who were admitted to 25 hospitals in mainland China with confirmed SARS-CoV-2 infection between December 1 ...
Yuanchao Zhu, Fei Zhao, Yubing Zhu, Xingang Li, Deshi Dong, Bolin Zhu, Jianchun Li, Xin Hu, Zinan Zhao, Wenfeng Xu, Yang Jv, Dandan Wang, Yingming Zheng, Yiwen Dong, Lu Li, Shilei Yang, Zhiyuan Teng, Ling Lu, Jingwei Zhu, Linzhe Du, Yunxin Liu, Lechuan Jia, Qiujv Zhang, Hui Ma, Ana Zhao, Hongliu Jiang, Xin Xu, Jinli Wang, Xuping Qian, Wei Zhang, Tingting Zheng, Chunxia Yang, Xuguang Chen, Kun Liu, Huanhuan Jiang, Dongxiang Qu, Jia Song, Hua Cheng, Wenfang Sun, Hanqiu Zhan, Xiao Li, Yafeng Wang, Aixia Wang, Li Liu, Lihua Yang, Nan Zhang, Shumin Chen, Jingjing Ma, Wei Liu, Xiaoxiang Du, Meiqin Zheng, Liyan Wan, Guangqing Du, Hangmei Liu, Pengfei Jin   +54 more
doaj   +2 more sources

Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience

Advanced Science
COVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID‐19 and
Liu Wu, Zhong‐Han He, Ling Huang, Xin Guo, Xu‐Yong Li, Hong‐Da Zhang, Man‐Hua Chen   +6 more
exaly   +2 more sources

Azvudine for the treatment of cancer patients with COVID-19: a multicenter, real-world, retrospective, cohort study [PDF]

BMC Cancer
Background Cancer patients are at an elevated risk for SARS-CoV-2 infection and require vigilant monitoring. The efficacy and safety of Azvudine in treating COVID-19 among this vulnerable group remain under-researched. Methods We conducted a multicenter,
Lei Li, Wenjie Liu, Ling Wang, Mengzhao Yang, Juan Wang, Guotao Li, Guowu Qian, Shixi Zhang, Donghai Liu, Hong Luo, Silin Li, Donghua Zhang, Zujiang Yu, Zhigang Ren   +13 more
doaj   +2 more sources